Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC-Reference-Cited by-同舟云学术

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Published:2013-09-24 Issue:12 Volume:3 Page:1404-1415
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discovery

Author:

Walter Annette O.,Sjin Robert Tjin Tham,Haringsma Henry J.,Ohashi Kadoaki,Sun Jing,Lee Kwangho,Dubrovskiy Aleksandr,Labenski Matthew,Zhu Zhendong,Wang Zhigang,Sheets Michael,St Martin Thia,Karp Russell,van Kalken Dan,Chaturvedi Prasoon,Niu Deqiang,Nacht Mariana,Petter Russell C.,Westlin William,Lin Kevin,Jaw-Tsai Sarah,Raponi Mitch,Van Dyke Terry,Etter Jeff,Weaver Zoe,Pao William,Singh Juswinder,Simmons Andrew D.,Harding Thomas C.,Allen Andrew

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 566 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors;Future Medicinal Chemistry;2024-08-29

2. Highly Sensitive 3D‐Nanoplasmonic‐Based Epidermal Growth Factor Receptor Mutation Multiplex Assay Chip for Liquid Biopsy;Small Science;2024-06-26

3. Covalent drug – An emerging framework for targeted drug development;Results in Chemistry;2024-06

4. Mechanism of targeting the mTOR pathway to regulate ferroptosis in NSCLC with different EGFR mutations;Oncology Letters;2024-05-01

5. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC;Clinical Cancer Research;2024-04-05